Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 2.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 10 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 7.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 6 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 3 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,dipyridamole -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - aspirin,dipyridamole -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - warfarin sodium - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - warfarin sodium - oral tablet - 3mg